Science News

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation...

NEW YORK--(BUSINESS WIRE)--WorldQuant Foundry, a venture studio dedicated to building world-changing companies driven by exponential technologies, today announced the appointment of Dr. Dmitry Green as Senior Quantum Computing Advisor. Dr. Green, an active physicist whose research and contributions are foundational to topological quantum computing technologies, joins WorldQuant Foundry's growing network of world-class advisors at a pivotal moment in the commercialization of quantum science. Wit...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement t...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). The Company also announced that it will host a virtual key opinion leader (KOL) event on Tuesday...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer signific...

SINGAPORE--(BUSINESS WIRE)--Horizon Quantum Holdings Ltd. (“Horizon Quantum”), which will become the holding company of Horizon Quantum Computing Pte. Ltd., a pioneer of software infrastructure for quantum applications, today announced expected new members of its board of directors and a key addition to its leadership team. Following the completion of Horizon Quantum’s merger (the “Business Combination”) with dMY Squared Technology Group, Inc. (“dMY”), the company expects to make the following...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update. “As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,” said Ron Cooper, President and Chief Executive Officer, enGe...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo. In Stage 2 of the study, which evaluated monthly dosing...

EVRY, France--(BUSINESS WIRE)--These results are very encouraging and show the potential of the product with data rarely seen in neuromuscular diseases at such an early stage....

CAMBRIDGE, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Abselion establishes US subsidiary at The Engine in Cambridge, MA to support more direct engagement with researchers in North America...